International Stem Cell Corp. (OTCMKTS:ISCO – Get Free Report) saw a large drop in short interest in the month of February. As of February 27th, there was short interest totaling 5,059 shares, a drop of 47.1% from the February 12th total of 9,559 shares. Approximately 0.4% of the company’s stock are sold short. Based on an average daily trading volume, of 2,928 shares, the short-interest ratio is presently 1.7 days. Based on an average daily trading volume, of 2,928 shares, the short-interest ratio is presently 1.7 days. Approximately 0.4% of the company’s stock are sold short.
International Stem Cell Stock Performance
International Stem Cell stock traded up $0.01 during mid-day trading on Friday, reaching $0.18. The stock had a trading volume of 20,100 shares, compared to its average volume of 3,953. The stock’s 50-day simple moving average is $0.15 and its 200-day simple moving average is $0.15. International Stem Cell has a fifty-two week low of $0.10 and a fifty-two week high of $0.27. The firm has a market capitalization of $1.41 million, a PE ratio of -8.81 and a beta of 0.13.
International Stem Cell Company Profile
International Stem Cell Corporation (OTCMKTS:ISCO) is a biotechnology company focused on the development and commercialization of human parthenogenetic stem cells (hpSC) for therapeutic and research applications. Parthenogenetic stem cells are derived from unfertilized human eggs and offer a scalable, ethically noncontroversial source of pluripotent cells. ISCO’s proprietary hpSC lines can be directed to differentiate into a wide variety of cell types, enabling preclinical programs in areas such as neurodegenerative disease, liver disease, diabetes and corneal regeneration.
In addition to its therapeutic pipeline, International Stem Cell maintains a research products division that supplies hpSC lines, differentiated cell populations and media formulations to academic institutions, biotechnology companies and contract research organizations.
Featured Articles
- Five stocks we like better than International Stem Cell
- Elon’s Biggest Move Yet?
- Iran isn’t the real war
- How JPMorgan’s $8,000 Gold Call Will Leave Most Retirement Accounts Behind
- Trump’s NEW Executive Order – BIG Changes Coming to Retirement Accounts
- J.P. Morgan is betting on this coin
Receive News & Ratings for International Stem Cell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for International Stem Cell and related companies with MarketBeat.com's FREE daily email newsletter.
